enavogliflozin eyedrop (DWRX2008) / Daewoong Pharma - LARVOL DELTA

Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species. (PubMed, Pharmaceuticals (Basel)) - "Ocular administration of enavogliflozin could be a potential therapeutic route for diabetic retinal complications, based on relative bioavailability and effective delivery to the posterior ocular segment. DWRX2008 would be applicable to humans with favorable PK profiles and minimal systemic adverse effect."

Journal • PK/PD data • Preclinical • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema (PRNewswire) - "Daewoong Therapeutics...is pioneering the development of the world's first-in-class eyedrop formulation for the treatment of diabetic eye diseases....Daewoong confirmed the approval from the Ministry of Food and Drug Safety (MFDS) for a phase 1 clinical trial plan for its investigational product DWRX2008. The inaugural study, set for Q4 of 2023, will assess the safety and pharmacokinetics of DWRX2008 across diverse dosages in both healthy Korean and Caucasian subjects."

New P1 trial • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology